Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in adults with moderate-to-severe bullous pemphigoid
MOH_2023-03-04_012390Phase 3Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Bullous Pemphigoid (BP) comparing Dupilumab with Placebo (2 arms). Primary endpoint: Accelerated remission off oral corticosteroids. Started Jan 2023; status: completed.
02
Drugs
03
Conditions
Bullous Pemphigoid (BP)
Beyond the preview
Go deeper on MOH_2023-03-04_012390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-03-04_012390.